Hep C Meds Patent Row Can't Stay In Minn., Fed. Circ. Says
The Federal Circuit on Wednesday refused to order that a patent lawsuit brought by the University of Minnesota against Gilead Sciences Inc. over hepatitis C medications be allowed to remain in...To view the full article, register now.
Already a subscriber? Click here to view full article